CRM1 is also a promising cancer drug target, and a small molecule inhibitor of CRM1 named Selinexor is currently in more than 40 clinical trials for a variety of cancers (clinicaltrials.gov) (Lapalombella et al., 2012; Etchin et al., 2013; Sun et al., 2013; Fung and Chook, 2014; Xu et al., 2015). Here, XPO1 is linked to cancer.